ATE382615T1 - Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung - Google Patents

Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung

Info

Publication number
ATE382615T1
ATE382615T1 AT01909008T AT01909008T ATE382615T1 AT E382615 T1 ATE382615 T1 AT E382615T1 AT 01909008 T AT01909008 T AT 01909008T AT 01909008 T AT01909008 T AT 01909008T AT E382615 T1 ATE382615 T1 AT E382615T1
Authority
AT
Austria
Prior art keywords
chromes
tocotrienols
tocopherols
side chain
chain derivatives
Prior art date
Application number
AT01909008T
Other languages
English (en)
Inventor
Robert Sanders
Kimberly Kline
Laurence Hurley
Robb Gardner
Marla Menchaca
Weiping Yu
Puthucode Ramanan
Shenquan Liu
Karen Israel
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/502,592 external-priority patent/US6770672B1/en
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of ATE382615T1 publication Critical patent/ATE382615T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
AT01909008T 2000-02-11 2001-02-09 Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung ATE382615T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/502,592 US6770672B1 (en) 1998-09-23 2000-02-11 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof

Publications (1)

Publication Number Publication Date
ATE382615T1 true ATE382615T1 (de) 2008-01-15

Family

ID=23998504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01909008T ATE382615T1 (de) 2000-02-11 2001-02-09 Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung

Country Status (14)

Country Link
US (2) US7312232B2 (de)
EP (1) EP1254130B1 (de)
JP (1) JP2004504268A (de)
KR (1) KR100847678B1 (de)
CN (1) CN1243000C (de)
AT (1) ATE382615T1 (de)
AU (2) AU2001236805B2 (de)
CA (1) CA2399802C (de)
DE (1) DE60132171D1 (de)
IL (2) IL151108A0 (de)
NZ (1) NZ520798A (de)
RU (1) RU2263672C2 (de)
WO (1) WO2001058889A1 (de)
ZA (1) ZA200206243B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
RU2263672C2 (ru) 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
CN1262274C (zh) * 2000-11-14 2006-07-05 生命健康科学有限公司 磷酸盐衍生物复合物
CA2453823C (en) * 2001-07-27 2010-12-21 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
CN1604772A (zh) * 2001-12-13 2005-04-06 生命健康科学有限公司 化合物的透皮转运
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
CA2513427C (en) * 2003-01-17 2012-03-27 Vital Health Sciences Pty Ltd. Compounds having anti-proliferative properties
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
EP1664067A2 (de) * 2003-09-15 2006-06-07 DSM IP Assets B.V. NEUE ROUTE ZU alpha-TOCOPHEROL, alpha-TOCOPHERYLALKANOATEN UND VORSTUFEN DAVON
JP4847437B2 (ja) 2004-03-03 2011-12-28 バイタル ヘルス サイエンシズ プロプライアタリー リミティド アルカロイド製剤
KR20070108382A (ko) * 2005-03-03 2007-11-09 바이탈 헬스 사이언시즈 피티와이 리미티드 항암성 화합물
MX2007015949A (es) 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
EP1973547A1 (de) * 2005-12-23 2008-10-01 Vital Health Sciences Pty Ltd. Verbindungen mit zytokin-modulierenden eigenschaften
JP5256049B2 (ja) * 2006-02-21 2013-08-07 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 抗癌剤
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
US8288369B2 (en) * 2006-06-27 2012-10-16 University Of South Florida Delta-tocotrienol treatment and prevention of pancreatic cancer
US20100292316A1 (en) * 2007-07-18 2010-11-18 Research Development Foundation Improved therapeutic methods and compositions comprising chroman ring compounds
NZ602579A (en) 2008-03-14 2013-12-20 Stephen John Ralph Mitochondrially delivered anti-cancer compounds
EP2419414A4 (de) * 2009-04-13 2013-12-04 Univ Ohio State Res Found Mittel zur aktivierung der protein-phosphatase 2a
WO2010121111A1 (en) 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2794734C (en) 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
EP2685992A4 (de) 2011-03-15 2014-09-10 Phosphagenics Ltd Aminochinoline als kinasehemmer
CN104470358A (zh) * 2012-05-18 2015-03-25 俄亥俄州立大学 用于改善肝功能的方法
CA2875975A1 (en) 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
IN2014KN02893A (de) * 2012-06-13 2015-05-08 Cytec Tech Corp
AU2014318014C1 (en) * 2013-09-06 2018-11-15 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease
MX2016003215A (es) 2013-09-13 2016-11-25 Univ Arkansas Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion.
US20160324914A1 (en) 2015-05-05 2016-11-10 Tocol Pharmaceuticals, Llc Use of rice bran oil distillate extract for prevention and mitigation of the effects of radiation
CN105078963B (zh) * 2015-09-29 2018-06-22 中山大学 α-生育酚在制备治疗血吸虫病药物中的应用
CA3007587C (en) 2015-12-09 2023-12-05 Phosphagenics Limited Pharmaceutical formulation
BR112019012946A2 (pt) 2016-12-21 2019-11-26 Avecho Biotechnology Ltd processo
KR20180002728U (ko) 2017-03-10 2018-09-19 주식회사 두울온돌침대 전열 매트리스
CA3135920A1 (en) * 2020-10-28 2022-04-28 Hermay Labs Corporation SILENT LABLE AND COHERENT REDOX ANALOGS FOR VITAMIN E ENRICHMENT

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5118954B2 (de) 1972-02-04 1976-06-14
CS172015B1 (de) 1974-05-12 1976-12-29
US4181725A (en) 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1979000401A1 (en) 1977-12-16 1979-07-12 Nisshin Flour Milling Co Anti-tumor agent
JPS6056155B2 (ja) 1978-12-04 1985-12-09 エーザイ株式会社 クロマニルオキシ脂肪酸同族体
US4457918A (en) * 1982-05-12 1984-07-03 The General Hospital Corporation Glycosides of vitamins A, E and K
DE3309159A1 (de) 1983-03-15 1984-09-20 Basf Ag, 6700 Ludwigshafen Neue optisch aktive chromanderivate, verfahren zu deren herstellung sowie neue zwischenprodukte
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4617317A (en) 1984-10-31 1986-10-14 Bennet Justin D Method of treating ulcerative colitis
JPS63500175A (ja) 1985-05-22 1988-01-21 リポソ−ム　テクノロジ−，インコ−ポレイテツド リポソ−ム吸入法および吸入システム
US4665204A (en) * 1985-06-27 1987-05-12 Henkel Corporation Diester derivatives of tocopherol
JPS63303049A (ja) 1987-06-04 1988-12-09 Shinagawa Refract Co Ltd 繊維強化ガラス質溶射材料
JPS6441727A (en) 1987-08-07 1989-02-14 Toshiba Corp Cooking unit
US5610180A (en) * 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
US5198432A (en) 1988-01-29 1993-03-30 Center For Innovative Technology Method of preventing chlorohydrocarbon toxicity using sterol derivatives
US5260294A (en) 1988-08-09 1993-11-09 Hoffman-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
JPH02215778A (ja) * 1989-02-14 1990-08-28 Kuraray Co Ltd ３，４―ジヒドロ―２ｈ―ベンゾピラン誘導体及びその医薬用途
JPH03206089A (ja) 1990-01-05 1991-09-09 Eisai Co Ltd 新規ビタミンｅ誘導体及びその製造方法
DE4014708C2 (de) 1990-05-08 1994-03-10 Heidelberger Druckmasch Ag Verfahren zum Ermitteln von Registerfehlern
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
FR2672601B1 (fr) 1991-02-08 1994-10-14 Synthelabo Derives de benzo-1,5-thiazepine, leur preparation et leur application en therapeutique.
JPH05213982A (ja) 1991-03-26 1993-08-24 Dainippon Ink & Chem Inc オリゴ糖トコフェロール配糖体及び硫酸化オリゴ糖トコフェロール配糖体並びにこれを有効成分とする抗ウイルス剤
FR2676056B1 (fr) * 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0636618A1 (de) 1991-06-04 1995-02-01 Marigen S.A. Spontan dispergierbare Konzentrate und Mikroemulsionen mit Vitamin-E-Verbindungen zur Herstellung von Arzneimitteln mit Antitumoraler Wirksamkeit
US5135945A (en) * 1991-06-05 1992-08-04 Merrell Dow Pharmaceuticals Inc. Cholesterol-lowering tocopherol analogs
CA2124086A1 (en) 1991-11-22 1993-05-27 Ronald H. Lane Tocotrienols and tocotrienol-like compounds and methods for their use
US5545660A (en) * 1992-04-07 1996-08-13 Merrell Pharmaceuticals Inc. Hydrazide derivatives of 3,4-dihydro-2H-1-benzopyrans
DE4215536A1 (de) * 1992-05-12 1993-11-18 Basf Ag Cyan-Mischungen für den Farbstofftransfer
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5403834A (en) 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
IT1256264B (it) * 1992-12-31 1995-11-29 Lifegroup Spa N-acilderivati di idrossiammine dotati di attivita' scavenger ed utilizzabili nelle patologie acute e croniche correlate a fenomeni di perossidazione ed infiammazione
DE4304303C2 (de) 1993-01-22 1997-01-30 Pacific Corp Vitamin-E-Derivate mit einem quartären Stickstoffatom, Verfahren zu deren Herstellung und kosmetische Mittel enthaltend dieselben
CA2152693A1 (en) 1994-08-05 1996-02-06 Kazumi Ogata Therapeutic composition for pancreatitis
US5670255A (en) 1995-01-23 1997-09-23 Ppg Industries, Inc. Antioxidant compositions for coating substrates, substrates coated with the same and methods for inhibiting the oxidation of such compositions applied to a substrate
DE19504398A1 (de) * 1995-02-10 1996-08-14 Beiersdorf Ag Tocopherylglycoside, ihre Herstellung sowie ihre Verwendung als Tenside, als Antioxidantien sowie als der Zellalterung vorbeugender Wirkstoff in kosmetischen oder pharmazeutischen Zubereitungen
DE19523079A1 (de) 1995-06-26 1997-01-02 Basf Ag Ester und Amide der 9(Z)-Retinsäure
CA2179940A1 (en) 1995-07-18 1997-01-19 Kazumi Ogata Antiallergic composition comprising a phosphoric diester compound
US5798356A (en) 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
CA2186654A1 (en) 1995-10-13 1997-04-14 Masayuki Nakamura Phosphoric diester
JPH09301953A (ja) * 1996-03-12 1997-11-25 Sanwa Kagaku Kenkyusho Co Ltd マロン酸ジアミド誘導体及びその用途
JPH104489A (ja) * 1996-04-19 1998-01-06 Nikon Corp 画像入力装置
JPH09301969A (ja) * 1996-05-15 1997-11-25 Fuji Photo Film Co Ltd クロマン系化合物及びそれを使用する感熱記録材料
DK0815858T3 (da) 1996-07-01 2001-10-08 Nisshin Flour Milling Co Farmaceutisk præparat, der indeholder 9-cis-retinsyre-alfa-tocopherolester, til behandling af leukæmi
US6022560A (en) 1996-08-27 2000-02-08 Clarion Pharmaceuticals Inc. Pharmaceutical compositions, novel uses, and novel form of α-tocopherylphosphocholine
FR2754713B1 (fr) 1996-10-22 1999-01-08 Roc Sa Utilisation de complexes pour la preparation de compositions pour le traitement des peaux sensibles, procede de preparation et compositions hypoallergeniques
AU729355B2 (en) 1997-03-04 2001-02-01 Wisconsin Alumni Research Foundation Method of suppressing tumor growth with combinations of isoprenoids and statins
CA2220541A1 (en) 1997-11-07 1999-05-07 Mcgill University Analogs of vitamin e
US5917060A (en) * 1997-12-17 1999-06-29 Basf Aktiengesellschaft Preparation of chromanyl derivatives
US6770672B1 (en) 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2000016772A1 (en) * 1998-09-23 2000-03-30 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5990322A (en) 1999-03-09 1999-11-23 Sk Corporation Alpha-tocopherol cyclopropylates, the new vitamin E derivatives and method for producing the same
US6127382A (en) 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
RU2263672C2 (ru) 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
US20030236301A1 (en) 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
EP1520014A4 (de) * 2002-04-19 2006-01-25 Res Dev Foundation Mit tocopherol assoziiertes protein und verwendungen davon

Also Published As

Publication number Publication date
CA2399802C (en) 2009-12-08
DE60132171D1 (de) 2008-02-14
IL151108A0 (en) 2003-04-10
NZ520798A (en) 2004-05-28
IL151108A (en) 2006-08-01
RU2002124135A (ru) 2004-01-10
EP1254130B1 (de) 2008-01-02
CA2399802A1 (en) 2001-08-16
RU2263672C2 (ru) 2005-11-10
EP1254130A4 (de) 2003-04-23
JP2004504268A (ja) 2004-02-12
CN1243000C (zh) 2006-02-22
US20080119514A1 (en) 2008-05-22
WO2001058889A1 (en) 2001-08-16
AU2001236805B2 (en) 2005-07-14
AU3680501A (en) 2001-08-20
US7608638B2 (en) 2009-10-27
US20040235938A1 (en) 2004-11-25
US7312232B2 (en) 2007-12-25
KR100847678B1 (ko) 2008-07-23
ZA200206243B (en) 2009-10-28
CN1529701A (zh) 2004-09-15
KR20030005186A (ko) 2003-01-17
EP1254130A1 (de) 2002-11-06

Similar Documents

Publication Publication Date Title
ATE382615T1 (de) Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung
PT778277E (pt) Derivados heterociclicos substituidos como antagonistas do crf
DK1392666T3 (da) Biologisk aktive methylenblåt-derivater
ES2053609T3 (es) Derivados de urea inhibidores de lipoxigenasa.
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
DE69817802D1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
ATE222894T1 (de) Substituierte aminophenylisoxazolinderivate verwendbar als antimikrobielle agenzien
DE69716925D1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
ATE291024T1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
EA200100422A1 (ru) Производные мононитрата изосорбида и их использование в качестве сосудорасширяющих агентов с пониженной толерантностью
DK1042319T3 (da) Dihydrobenzofuraner
DE69425804T2 (de) Phosphonsäurediesterderivate
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
ATE327979T1 (de) Pyrazolinon-derivate
ATE232732T1 (de) 2',5'-phosphorthioat/phosphodiester- oligoadenylate und ihre antiviralen verwendungen
ATE278697T1 (de) Katalysatoren
ES2106199T3 (es) Derivado de nitroxialquilamida.
TR199801902A2 (xx) S�lfonamid ile s�bstit�e edilmi� kromanlar, bunlar� i�eren farmakolojik bile�imler.
DE59200787D1 (de) 6-Thiono-5,6-dihydro-dibenz[b,e]azepin-11-on-11-oxime und ihre Verwendung als retrovirale Mittel.
DE69912306D1 (de) 1,4-diaryl-2-fluor-1-buten-3-ol-verbindungen und ihre verwendung in der herstellung von 1,4-diaryl-2-fluor-1,3-butadien- und 1,4-diaryl-2-fluor-2-buten-verbindungen
PL373989A1 (en) Novel benzonaphthyridines
ATE293605T1 (de) Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren
DE60021914D1 (de) Triazatrinaphthyrinen und ihre verwendung
ECSP003624A (es) Nuevos compuestos espiro
ATE239015T1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties